Clinical characteristics of peristomal pyoderma gangrenosum: A Single Center Retrospective Observational Study.
Pyoderma gangrenosum
corticosteroid
prednisolone
tacrolimus
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
06
06
2022
received:
17
05
2022
accepted:
15
06
2022
pubmed:
6
7
2022
medline:
4
11
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
Peristomal pyoderma gangrenosum (PPG), a variant of pyoderma gangrenosum, occurs adjacent to intestinal or urinary stomas and are typically seen in patients with active inflammatory bowel diseases (IBD). The present study evaluated 14 cases of PPG among 537 patients that had undergone ostomy surgery at Asahikawa Medical University Hospital from January 2017 to December 2021. The incidence of PPG among ostomy cases was calculated as 1.01 per 100-person-years. The median period from ostomy surgery to PPG onset was 192.5 days (36-1224 days). Significant differences in gender and ostomy subtype were observed in patients with PPG compared to all patients that had undergone ostomy surgery. IBD prevalence was comparable between groups. Topical corticosteroids or tacrolimus were sufficient for controlling PPG lesions in all cases other than one case controlled with oral prednisolone administered for a separate condition. Clinicians should be aware of recent developments in IBD therapies that may modify the risk of developing PPG. The present study results add to current knowledge of the pathogenesis of PPG.
Identifiants
pubmed: 35789032
doi: 10.1111/1346-8138.16504
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1178-1182Informations de copyright
© 2022 Japanese Dermatological Association.
Références
Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161:1118-32.
Wu XR, Mukewar S, Kiran RP, Remzi FH, Hammel J, Shen B. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis. 2013;7:e171-7.
Barbosa NS, Tolkachjov SN, el-Azhary RA, Davis MDP, Camilleri MJ, McEvoy MT, et al. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: the Mayo Clinic experience, 1996 through 2013. J Am Acad Dermatol. 2016;75:931-9.
Afifi L, Sanchez IM, Wallace MM, Braswell SF, Ortega-Loayza AG, Shinkai K. Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review. J Am Acad Dermatol. 2018;78:1195-204.
Plumptre I, Knabel D, Tomecki K. Pyoderma gangrenosum: a review for the gastroenterologist. Inflamm Bowel Dis. 2018;24:2510-7.
Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalization and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3-13.
Kikuchi N, Yamamoto T. Peristomal pyoderma gangrenosum: report on 11 cases. J Dermatol. 2020;47:e282-3.
Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn J, Surgery R, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110-21.
Kuwahara E, Murakami Y, Nakamura T. Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J Gastroenterol. 2017;52:185-93.
Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14:1-14.
Szántó M, Dózsa A, Antal D, Szabó K, Kemény L, Bai P. Targeting the gut-skin axis-probiotics as new tools for skin disorder management? Exp Dermatol. 2019;28:1210-8.
Join-Lambert O, Duchatelet S, Delage M, Miskinyte S, Coignard H, Lemarchand N, et al. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients. Presented in poster form at the 23rd European Academy of Dermatology and Venereology Congress, Amsterda. J Am Acad Dermatol. 2015;73:S66-9.
Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal cancer. Cancer Cell. 2018;33:954-64.
Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-5.